Durata, Cubist Antibiotics Poised For Approval, Additional Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Dalbavancin may have to deal with a liver function issue, but both it and tedizolid receive overwhelming endorsements from FDA’s Anti-Infective Drugs Advisory Committee, setting the ABSSSI products up to be the first QIDP approvals.